Investigational Drug Information for Semapimod
✉ Email this page to a colleague
What is the drug development status for Semapimod?
Semapimod is an investigational drug.
There have been 5 clinical trials for Semapimod.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2003.
The most common disease conditions in clinical trials are Crohn Disease and [disabled in preview]. The leading clinical trial sponsors are Ferring Pharmaceuticals and [disabled in preview].
Summary for Semapimod
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 23 |
| WIPO Patent Applications | 4 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2003-07-01) |
| Vendors | 16 |
Recent Clinical Trials for Semapimod
| Title | Sponsor | Phase |
|---|---|---|
| Single Ascending Dose Study of Oral CPSI-2364 (Semapimod) | Ferring Pharmaceuticals | Phase 1 |
| Extension Study of Semapimod 60 mg IV x 3 Days | Ferring Pharmaceuticals | Phase 2 |
| Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease | Ferring Pharmaceuticals | Phase 2 |
Clinical Trial Summary for Semapimod
Top disease conditions for Semapimod
Top clinical trial sponsors for Semapimod
US Patents for Semapimod
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
